Tier 2 — strong

Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI

Simic P, Vela Parada XF, Parikh SM, Dellinger R, Guarente LP, Rhee EP
BMC nephrology 2020 21; 1; 342

Bibliography

PubMed
PMID 32791973
PubMed Central
PMC7427083
DOI
10.1186/s12882-020-02006-1
Funding
Indexed grant support includes NIDDK NIH HHS. The complete funding declaration is not specified in the accessible abstract.
Competing interests
Two authors were employees of Elysium Health.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample24 hospitalized patients with acute kidney injury
InterventionEscalating NR/pterostilbene combinations, up to 1000/200 mg twice daily, versus placebo
Duration2 days of treatment
EndpointsBlood NAD+; safety laboratory measures; tolerability

What the study showed, in plain terms

Combined NR and pterostilbene increased whole-blood NAD+ during a short safety study in acute kidney injury.

Key findings

Three of 20 active-treatment recipients reported minor gastrointestinal symptoms.

What this study can and cannot tell us

Small dose-escalation cohorts with only four placebo recipients overall; the trial did not establish kidney recovery or prevention of kidney failure.

Related papers in the corpus

Tier 4
Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial
Holmes HE et al. · Frontiers in aging · 2026
Tier 2
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Dellinger RW et al. · Hepatology (Baltimore, Md.) · 2023
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals
Jensen JB et al. · JCI insight · 2022
Tier 2
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
de la Rubia JE et al. · Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019
Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology